Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation

Chua, Terence C.; Alzahrani, Abdulaziz M.; Saxena, Akshat; Zhao, Jing; Morris, David L.

doi:10.1016/j.jamcollsurg.2010.06.011

Cited by 23 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several other studies focused on repeat CRS–HIPEC procedures and concluded that this was feasible, with a large group of patients remaining disease‐free afterwards. Recurrence rates after first CRS–HIPEC in the present series were slightly higher than those in other studies, with reported recurrence rates tending to be below 50 per cent.…”

Section: Discussionmentioning

confidence: 99%

“…After treatment with CRS-HIPEC, the 10-year overall survival (OS) rate is 50-60 per cent 4,5,7 . Although CRS-HIPEC is a major surgical procedure that significantly impacts quality of life, many patients seem willing to undergo further time of initial diagnosis, with increased abdominal girth, abdominal discomfort, nausea, vomiting or weight loss 11 . Clinical symptoms are associated with poorer survival 11 .…”

Section: Introductionmentioning

confidence: 99%

“…Although CRS-HIPEC is a major surgical procedure that significantly impacts quality of life, many patients seem willing to undergo further time of initial diagnosis, with increased abdominal girth, abdominal discomfort, nausea, vomiting or weight loss 11 . Clinical symptoms are associated with poorer survival 11 . Other prognostic factors include serum tumour markers and histological findings.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Factors influencing long‐term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms

et al. 2019

View full text Add to dashboard Cite

Background Pseudomyxoma peritonei (PMP) is a rare disease, most commonly of appendiceal origin. Treatment consists of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS–HIPEC). The aim of this study was to identify prognostic factors for recurrence and survival. Methods This was an observational study using a prospectively designed database containing consecutive patients with PMP originating from the appendix, undergoing CRS–HIPEC at a tertiary referral centre between 1996 and 2015. Histopathological slides were reassessed. Cox regression was used for multivariable analyses. Results Of 225 patients identified, 36 (16·0 per cent) were diagnosed with acellular mucin, 149 (66·2 per cent) had disseminated peritoneal adenomucinosis (DPAM) and 40 (17·8 per cent) had peritoneal mucinous carcinomatosis (PMCA). The 5‐year overall survival (OS) rates were 93, 69·8 and 55 per cent respectively. Recurrence was observed in 120 patients (53·3 per cent), 39 of whom (17·3 per cent) were treated with a second CRS–HIPEC procedure. Factors independently associated with poor disease‐free survival were six or seven affected regions (hazard ratio (HR) 6·01, 95 per cent c.i. 2·04 to 17·73), incomplete cytoreduction (R2a resection: HR 1·67, 1·05 to 2·65; R2b resection: HR 2·00, 1·07 to 3·73), and more than threefold raised carcinoembryonic antigen (CEA) and/or carbohydrate antigen (CA) 19‐9 level (HR 2·31, 1·30 to 4·11). Factors independently associated with poorer OS were male sex (HR 1·74, 1·09 to 2·77), incomplete cytoreduction (R2a resection: HR 1·87, 1·14 to 3·08; R2b resection: HR 2·28, 1·19 to 4·34), and more than threefold raised CEA and/or CA19‐9 level (HR 2·89, 1·36 to 6·16). Conclusion CEA and CA19‐9 levels raised more than threefold above the upper limit identify patients with PMP of appendiceal origin and poorer survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Factors influencing long‐term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Dans une étude hollandaise publiée en 2007, une dédif-férenciation est observée dans 20 % des récidives [10]. En 2011, en utilisant les classifications de Ronnett et de Bradley, Terence Chua rapporte 16 % d'évolutivité des PP de bas grade en haut grade [11]. Mais ce travail est critiqué dans la même revue par l'équipe de Kanwal [12] présente une série de 74 patients traités entre 1994 et 2009.…”

Section: éVolutivité Des Ppunclassified

Pathologie tumorale du péritoine : cas no 2 : une tumeur péritonéale récidivante

Sabourin

2015

Annales de Pathologie

View full text Add to dashboard Cite

“…In addition, approximately 7% of low-grade lesions have lymph node involvement and another 16% dedifferentiate into higher-grade lesions during the course of the disease. 4,5 The management of patients with PSD from appendiceal neoplasms is still a matter of intense debate. These patients have been traditionally treated with systemic chemotherapy or only debulking procedures.…”

Section: Introductionmentioning

confidence: 99%

Current Status and Future Directions in Appendiceal Cancer with Peritoneal Dissemination

Votanopoulos

Shen²,

Stewart³

et al. 2012

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation

Cited by 23 publications

References 18 publications

Factors influencing long‐term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms

Factors influencing long‐term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms

Pathologie tumorale du péritoine : cas no 2 : une tumeur péritonéale récidivante

Current Status and Future Directions in Appendiceal Cancer with Peritoneal Dissemination

Contact Info

Product

Resources

About